Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT07448285

PHASE3

Clinical Trial to Evaluate the Efficacy and Safety of Platelet-rich Plasma Infiltration in Chronic Omalgia

Sponsor: Biobizkaia Health Research Institute

View on ClinicalTrials.gov

Summary

The experimental group will receive intralesional injections of platelet-rich plasma, evaluating its ability to relieve pain and provide sustained improvement through biological modulation of the joint and tendon environment. In contrast, the control group will be treated with a combination of betamethasone and ropivacaine, representing the current standard of care for short-term inflammatory pain management. The comparison between these two options will determine whether platelet-rich plasma offers advantages in terms of clinical efficacy and duration of benefits. The results obtained could contribute significantly to the development of more effective protocols and more precise management guidelines for patients with chronic omalgia, thus addressing existing controversies and improving clinical practice.

Official title: Randomized Clinical Trial to Evaluate the Efficacy and Safety of Platelet-Rich Plasma (PRP) Injection Combined With Physical Exercise in Chronic Omalgia

Key Details

Gender

All

Age Range

35 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2026-02-24

Completion Date

2029-04

Last Updated

2026-03-04

Healthy Volunteers

Conditions

Chronic Pain

Interventions

BIOLOGICAL

Platelet-rich Plasma Local injection

Two procedures are considered for obtaining an equivalent PRP formulation, with the aim of establishing a contingency plan for possible situations such as a shortage of specific materials (extraction tubes) or the unavailability of a dedicated clean room for preparation under open circuit conditions. PRP produced in-house, following the open technique, is prepared in a laminar flow cabinet within an environment that complies with the standards of asepsis and Good Manufacturing Practices required for this type of preparation.

DRUG

betamethasone and Ropivacaine

consists of a mixture of 2 cc of betamethasone and 2 cc of ropivacaine. To prepare it, 2 cc of betamethasone will be extracted from an ampoule of injectable solution using a sterile syringe (without attaching the needle) and mixed with 2 cc of ropivacaine.

Inclusion Criteria: * Patients between 35 and 75 years of age, both inclusive. * Presence of pain in the affected shoulder for 3 or more months. * Body Mass Index (BMI) values between 20 and 27 kg/m2, including both values. * Confirmed diagnosis of chronic shoulder pain associated with rotator cuff tendinopathy, following an unfavorable response to standard treatment with analgesics and nonsteroidal anti-inflammatory drugs for 4-6 weeks. * Patients who agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Confirmed diagnosis of complete rotator cuff tear. * Patients with systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis). * Patients with diabetes mellitus. * Patients with hematological disorders (thrombopathy, thrombocytopenia, anemia with Hb\<9 g/dl). * Patients undergoing immunosuppressive treatment at the time of inclusion. * Patients undergoing treatment with intramuscular corticosteroids in the 3 months prior to the first administration of the trial treatment. * Patients undergoing treatment with nonsteroidal anti-inflammatory drugs (more than 10 consecutive days at usual doses), opioids, or oral corticosteroids during the 15 days prior to treatment in the study. * Patients with severe heart disease. * Patients with active cancer or cancer diagnosed in the last 5 years. * Patients who are taking a drug in clinical trials or have participated in any clinical trial (with an authorized or unauthorized product) in the 30 days prior to randomization. * Patients with any physical, social, or psychological condition that, in the opinion of the investigators, may affect the patient's participation in the trial or the validity of the data obtained from their participation in it. * Pregnant women. * Breastfeeding women. * Women of childbearing age\* who are unable or unwilling to use contraceptive methods with a failure rate of \<1% per year (bilateral tubal ligation, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) during the four-week treatment period.

Locations (2)

Hospital Universitario Cruces

Barakaldo, Bizkaia, Spain

Hospital Universitario Basurto

Bilbao, Bizkaia, Spain